How does Donanemab compare to other Alzheimers drugs , Morning in America
Eli Lilly and Co. is seeking FDA approval for Donanemab. If cleared, it would be only the second Alzheimers treatment convincingly shown to delay the mindrobbing disease. Dr. Ian Smith weighs out the pros and cons of this drug s ability to slow Alzheimer s. Watch, MorningInAmerica: , Alzheimers, FDA, Donanemab Start your day with Morning in America, NewsNation s live threehour national morning newscast hosted by Adrienne Bankert. Weekdays starting at 7a, 6C. ,MorningInAmerica NewsNation is your source for factbased, unbiased news for all America. More from NewsNation: Get our app: Find us on cable: How to watch on TV or streaming:
|
|